Remote Screening for Asymptomatic Atrial Fibrillation - The AMALFI Randomized Clinical Trial

Authors: Rohan Wijesurendra, DPhil, Guilherme Pessoa-Amorim, DPhil, Georgina Buck, MSc, Charlie Harper, DPhil, Richard Bulbulia, MD, Alison Offer, PhD, Nicholas R. Jones, DPhil, Christine A’Court, MA, Rijo Kurien, MSc, Karen Taylor, MSc, Barbara Casadei, DPhil, Louise Bowman, MD.

Summary:

Results from the UK study on 5040 individuals in primary care looking at the long-term efficacy of AF screening in older individuals at moderate to high risk of stroke using 14-day (Zio), patch-based continuous ambulatory electrocardiogram (ECG) monitoring.

Key Findings:

UK study at Oxford in JAMA on 5040 patients >65 y/o with CHA2DS2VASc score of 3 for men and 4 for women who were randomized to usual care vs Zio 14-day LTCM home enrollment ordered from primary care

At 2.5 years post-randomization, AF detected in 6.8% in Zio vs 5.4% in control group (p=0.03).

Time to diagnosis for Zio monitored group was 103 days vs 530 in control group.

The content on iRhythm Academy is provided for general educational purposes only and should not be considered the exclusive source for this type of information. This training does not replace or supersede approved labeling. The content will be shared with physicians and healthcare professionals who seek a deeper understanding of the operation and use of iRhythm products and services with the intent of enhancing their knowledge of features and operations described in the clinician manuals. At all times, it is the professional responsibility of the physicians and healthcare professionals to exercise independent clinical judgment in a particular situation. The device and service functionality and programming described on iRhythm Academy are based on its products and services, and can be referenced in the labeling and reference manuals. This website is intended for healthcare professionals and not intended for patients or consumers.